Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

l trial for elagolix, the  most advanced clinical program in the Company's pipeline, will fail to support the additional Phase III clinical trial required for regulatory approval; risk that the elagolix Phase III program overall will encounter delays for regulatory or other reasons; risk that the elagolix Phase III clinical program will fail to demonstrate that elagolix is safe and effective for the treatment of endometriosis or support filings for regulatory approval; risk that the uterine fibroid elagolix clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of uterine fibroids; and  risks associated with the Company's dependence on corporate collaborators for Phase III development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the rest of the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective; and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's repor
'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Calif. , Feb. 26, 2015 Protiviti ... the latest version of the Governance Portal , ... governance, risk and compliance (GRC) tasks across multiple business ... been updated to help customers better align their controls ... the Treadway Commission ) requirements. In response to client ...
(Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015 The ... navigate this ever-changing arena, Frost & Sullivan will host its ... & Sullivan Executive MindXchange , March 8 to 10, at ... San Diego, Calif. This event is ... connected healthcare leaders to discuss industry disruptions and how to ...
(Date:2/26/2015)... 2015 RURO, Inc., a leading LIMS, ... 6.2 – the latest update to the bestselling commercial-off-the-shelf ... of a quick and easy method to gain better ... version, RURO engineering has enhanced the system’s support for ... amounts of sample records. , "FreezerPro has become ...
(Date:2/26/2015)... , Feb. 26, 2015 Tauriga Sciences, ... sciences company with interests in the natural wellness sector ... announced today that its products will be featured at ... Capital Partners, 27 th Annual Growth Stock Conference ... located at 1 Ritz Carlton Drive, Dana ...
Breaking Biology Technology:Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3RURO Releases FreezerPro® version 6.2 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4
... CEO Darwin Smith may or may not have brought down ... was 1983, and Wisconsin had just elected liberal Democrat Tony ... with an income tax increase, and Smith issued a dire ... business climate. , ,Two years later, Smith moved Kimberly-Clark's corporate ...
... Wis. - William R. Hendee will retire effective June ... at the Medical College of Wisconsin , and devote ... who also will retire as president of the MCW Research ... College conducts a national search for a permanent successor it ...
... way we think about work life isn't. Everyone knows ... nobody is ready to translate this into actual practice, ... life satisfaction." , ,This quote by a Dutch ... Suzan Lewis and Richenda Gambles entitled, "Work-Personal Life Harmonization: ...
Cached Biology Technology:RedPrairie: Will they stay, or will they go? 2RedPrairie: Will they stay, or will they go? 3RedPrairie: Will they stay, or will they go? 4Medical College grad school dean Bill Hendee to retire 2Work-life imbalance - A global problem getting worse 2Work-life imbalance - A global problem getting worse 3Work-life imbalance - A global problem getting worse 4Work-life imbalance - A global problem getting worse 5
(Date:2/13/2015)... -- ACT Genomics Co., Ltd., a cancer molecular ... genomic information into precision diagnosis and personalized treatments, ... million in the its first private funding round. ... , ACT Genomics has developed comprehensive cancer ... implement next generation sequencing (NGS) and multiplex molecular ...
(Date:2/10/2015)... 2015  Alere Inc. (NYSE: ALR), a global ... for the quarter ended December 31, 2014. ... of Alere said, "We made substantial progress in ... global leader in rapid diagnostics and delivering against ... divestiture in early January enabled us to substantially ...
(Date:2/5/2015)...   Epic Sciences , a precision diagnostics company dedicated ... Murali Prahalad , Ph.D., president and CEO, is scheduled to ... 2015: Silicon Valley, which is taking place at the Computer ... on January 26-28, 2015. Dr. Prahalad will ... Last year, Epic Sciences was a finalist in the PMWC,s ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35
... July 15, 2013 Dr. Jeffrey Trent, President and ... will discuss state-of-the-art genomics research July 16 at the ... former Scientific Director of the National Human Genome Research ... at Brookings, 2nd annual State of Biomedical Innovation Conference, ...
... Ice Age, as the world began to warm, a swath ... brief pulse of biological productivity 14,000 years ago, this stretch ... tiny creatures, who thrived in large numbers until the productivity ... Researchers have hypothesized that iron sparked this surge ...
... by slugs may prevent key grassland species from taking ... new research has shown., Work by scientists at Newcastle ... on grassland biodiversity and how this might inform future ... through a gardener,s prize petunias or strawberry patch, still ...
Cached Biology News:TGen President Dr. Jeffrey Trent speaks at Brookings Institution biomedical conference 2Scientists solve a 14,000-year-old ocean mystery 2Scientists solve a 14,000-year-old ocean mystery 3Grazing slugs hinder grassland restoration 2
NuParaffin Kit Application: Flow Cytometry Reactivity: Human...
Request Info...
...
Highly efficient electroporation solution suitable for transfection of plasmid DNA, oligonucleotides and siRNA. Compatible with all common electroporators....
Biology Products: